All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-5T4 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human 5T4. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-5T4 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Chronic lymphocytic leukemia (CLL).
CAR Construction : Fig.1 Engineered antibody binding in MDAMB435/5T4 cell. The binding of unconjugated cysteine mutant anti-5T4 antibodies to MDAMB435 cells expressing 5T4 antigen (MDAMB435/5T4) expressed as mean calculated fluorescence, compared with binding of parental anti-5T4 antibody comprising a wild type IgG1 Fc domain. |
CAR Construction : Fig.2 Internalization of compounds at 4h on MDAMB435/5t4 cells. Internalization of cysteine variant antibodies conjugated with mcMMAD compared with the internalization of wild type antibody conjugated with mcMMAD (5T4-IgG1-mcMMAD) and wild type antibody which was not conjugated (wt IgG1). |
CAR Construction : Fig.3 Comprising panels A and B, show that engineered cysteine variant antibodies do not exhibit altered Fc effector activity compared with wild type parental antibody. Cysteine variants 5-T4-E380C, 5T4-L398C, 5T4-V422C, and 5T4-L443C demonstrate the same ADCC activity as wild type parental antibody (5T4) in cells expressing 5T4 (MDA435/5T4). |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-5T4 (L443C) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP2482). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION